Nevertheless, human PDACs are highly resistant to anti‐PD1 or anti‐cytotoxic T lymphocyte‐associated antigen‐4 (CTLA4)‐based immunotherapy except a few microsatellite‐unstable cases, suggesting that SMAD4 loss alone could be insufficient to promote tumor response to checkpoint blockade. Here, CTLA4 is linked to neoplasm.